Adherent PBMC treated with B7.H1 blocking antibody or IL-10 blocking antibody. PBMC stimulated as previous. (A) CD8+ cellular proliferation (top row) and CD8+ T cell IFNγ (bottom row), compared to PD-1 (x-axis) in PBMC from negative control (left), asymptomatic VL (middle), and symptomatic VL (right) dogs, with isotype control (left), anti-IL-10 antibody (center), or anti-B7.H1 antibody treatment (right). (B) CD8+ cellular proliferation, n=13. (C) CD8+ PBMC IFNγ intracellular production, n=22. *p<0.05, **p<0.01, via one way ANOVA with Tukey’s post-test.